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Ribonucleotide reductase subunits M1 (RRM1) and M2 (RRM2) are involved in the metabolism of gemcitabine (20,20-
difluorodeoxycytidine), which is used for the treatment of nonsmall cell lung cancer. The mRNA expression of RRM1 and RRM2 in
tumours from lung adenocarcinoma patients treated with docetaxel/gemcitabine was assessed and the results correlated with clinical
outcome. RMM1 and RMM2 mRNA levels were determined by quantitative real-time PCR in primary tumours of previously
untreated patients with advanced lung adenocarcinoma who were subsequently treated with docetaxel/gemcitabine. Amplification
was successful in 42 (79%) of 53 enrolled patients. Low levels of RRM2 mRNA were associated with response to treatment
(Po 0.001). Patients with the lowest expression levels of RRM1 had a significantly longer time to progression (P¼0.044) and overall
survival (P¼0.02) than patients with the highest levels. Patients with low levels of both RRM1 and RRM2 had a significantly higher
response rate (60 vs 14.2%; P¼0.049), time to progression (9.9 vs 2.3 months; P¼0.003) and overall survival (15.4 vs 3.6; P¼0.031)
than patients with high levels of both RRM1 and RRM2. Ribonucleotide reductase subunit M1 and RRM2 mRNA expression in lung
adenocarcinoma tumours is associated with clinical outcome to docetaxel/gemcitabine. Prospective studies are warranted to evaluate
the role of these markers in tailoring chemotherapy.
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Platinum-based chemotherapy is the standard treatment for
patients with inoperable locally advanced and metastatic nonsmall
cell lung cancer (NSCLC) as it prolongs survival and improves
quality of life (Souquet et al, 1993). However, randomised studies
have reported no substantial difference in terms of efficacy
between various platinum-based regimens using new anticancer
drugs (Schiller et al, 2002). Moreover, the toxicity profile of
cisplatin can influence the patients’ quality of life. Several
randomised phase III studies have demonstrated that nonplati-
num-containing regimens have substantial efficacy against
advanced/metastatic NSCLC with a more favourable toxicity
profile than the corresponding cisplatin-based regimens (Douillard
et al, 2001; Georgoulias et al, 2001, 2005; Kosmidis et al, 2002).
Gemcitabine (20,20-difluorodeoxycytidine) is a deoxycytidine
analogue that is incorporated into DNA and competitively inhibits
DNA synthesis (Chabner, 1996). Ribonucleotide reductase (RR) is
an enzyme of central importance in DNA synthesis (Cory and Sato,
1983). Ribonucleotide reductase catalyses the conversion of
ribonucleotide 50-diphosphates to their 20-deoxynucleotide forms,
a rate-limiting step in the production of 20-deoxyribonucleoside 50-
triphosphates (dNTP) required for DNA synthesis (Cory, 1997).
The RR holoenzyme consists of M1 (RRM1) and M2 (RRM2)
subunits, and the holoenzymatic activity is modulated by levels of
the M2 subunit (RRM2) (Tanaka et al, 2000).
RRM1, localised in 11p15.5, also acts as a putative tumour
suppressor gene (Pitterle et al, 1999). 11p15.5, also known as
LOH11A, is frequently lost in NSCLC, and loss of heterozygosity in
this region has been correlated with poor survival in resected
NSCLC patients (Bepler et al, 2002). However, RRM1 over-
expression was related to gemcitabine resistance in human
oropharyngeal epidermoid carcinoma KB cells (Goan et al,
1999). Ribonucleotide reductase subunit M1 mRNA expression
by quantitative PCR significantly influenced time to progression
and survival in stage IV NSCLC patients treated with gemcitabine/
cisplatin (Rosell et al, 2003). Two subsequent studies confirmed
that RRM1 mRNA expression levels were able to identify stage IV
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with gemcitabine/cisplatin (Rosell et al, 2004; Ceppi et al, 2006).
Ribonucleotide reductase subunit M2 itself is a dimer of two
44kDa moieties, each containing a tyrosine free radical and
nonhaeme iron (Thelander et al, 1985). Cells overexpressing RRM2
exhibit enhanced cellular invasiveness (Zhou et al, 1998), through
activation of nuclear factor kB (NF-kB), which increases MMP-9
expression (Duxbury and Whang, 2007). There is limited
information concerning the effect of tumoral RRM2 expression
and response to gemcitabine in human tumours.
In a randomised multicentre trial comparing docetaxel/cisplatin
and docetaxel/gemcitabine as front-line chemotherapy in NSCLC
patients, a significantly higher objective response rate was
achieved with docetaxel/gemcitabine in adenocarcinoma than in
nonadenocarcinoma patients (Georgoulias et al, 2001). To further
investigate this issue, we have carried out a multicentre phase II
study to evaluate the impact of RRM1 and RRM2 mRNA
expression in the tumours of lung adenocarcinoma patients
treated with docetaxel/gemcitabine.
MATERIALS AND METHODS
Patients
Chemotherapy-naive patients with inoperable, histologically con-
firmed stage IIIB and IV adenocarcinoma of the lung and Eastern
Cooperative Oncology Group performance status (PS) 0–2 were
enrolled. Other eligibility criteria were the same as those reported
in previous studies (Georgoulias et al, 2001). The study was
approved by the ethics and scientific committees of the
participating hospitals and was conducted according to the
Declaration of Helsinki. All patients gave their signed informed
consent prior to study entry. Gemcitabine (Gemzar; Eli Lilly,
Indianapolis, IN, USA) (1000mgm
 2 on days 1 and 8) and
docetaxel (Taxotere; Sanofi-Aventis, Collegeville, NJ, USA)
(100mgm
 2 on day 8) with human granulocyte colony-stimulating
factor support were administered every 3 weeks as previously
described (Georgoulias et al, 2001), with dose adjustment if needed
due to haematological and nonhaematological toxicity (Georgoulias
et al, 2001). Patients were evaluated at baseline and before each
third cycle of chemotherapy (Georgoulias et al, 2001).
RRM1 and RRM2 assessment
All paraffin-embedded tumours were reviewed by an independent
pathologist to ensure the validity of the specimen and define the
most appropriate tumour area for microdissection. From each
paraffin block of tumour, serial sections with a thickness of 5mm
were prepared and then stained with nuclear Fast Red (Sigma-
Aldrich, St Louis, MO, USA).
RRM1 and RRM2 gene expression analysis was performed in
RNA isolated from tumour tissue specimens after laser capture
microdissection (Palm, Oberlensheim, Germany), according to a
proprietary procedure (patent pending EP05077417.3) of Pangaea
Biotech, SA.
The RT-PCR was carried out with the addition of 2.5mlo f
template cDNA to 6.25ml Taqman Universal Master Mix (AB;
Applied Biosystems, Foster City, CA, USA) with the addition of
specific primers and probe for each gene and adjusted with
diethylpyrocarbonate-treated water in a final volume of 12.5ml per
reaction. The primer and probe sets were designed using Primer
Express 2.0 Software (AB). Quantification of gene expression was
performed using the ABI Prism 7900HT Sequence Detection
System (AB). Primers and probe were designed according to the
Ref Seq L10342 for RRM1 and NM_001034 for RRM2 (http://
www.ncbi.nlm.nih.gov/LocusLink). The primers and 50-labelled
fluorescent reporter dye (6FAM) probe were as follows: RRM1:
forward 50-ACTAAGCACCCTGACTATGCTATCC-30, reverse 50-CT
TCCATCACATCACTGAACACTTT-30, probe 50-CAGCCAGGATCG
CTGTCTCTAACTTGCA-30; RRM2: forward 50-CCTGGCCAGCAA
GACCG-30, reverse 50-TAGTTTTCGGCTCCGTGGG-30, probe 50-
CGAGGAGGATCTTCCAGGA-30; b-actin: forward 50-TGAGCGCG
GCTACAGCTT-30, reverse 50-TCCTTAATGTCACGCACGATTT-30,
probe 50-ACCACCACGGCCGAGCGG-30.
Relative gene-expression quantification was performed according
to the comparative Ct method using b-actin as an endogenous
control and commercial RNA controls (Stratagene, La Jolla, CA,
USA) as calibrators. Final results were determined as follows:
2
 (DCt sample DCt calibrator), where DCt values of the calibrator and
sample are determined by subtracting the Ct value of the target
gene from the value of the housekeeping gene, b-actin. In all
experiments, only triplicates with a standard deviation (s.d.) of the
Ct value o0.20 were accepted. In addition, genomic DNA
contamination was excluded by nonreverse transcript RNA for
each sample analysed.
Study design
The trial was designed as a prospective phase II trial focused on
biomarker analysis in lung adenocarcinoma patients treated with
docetaxel/gemcitabine. The primary end point was the overall
response rate. The study followed the optimal Simon two-step
design. If a minimum objective response rate exceeding 35% was
observed in the first 16 patients, 39 additional patients were
enrolled in a 2-year (December 2001 to December 2003) time
period (a¼0.05, power 80%). All efficacy and toxicity results were
assessed for all enrolled patients on an intent-to-treat basis.
Median time to progression and overall survival were calculated
from the start of treatment to the first documented disease
progression or death, respectively. Quantitative PCR analyses
yielded values that were expressed as ratios between two absolute
measurements (gene of interest: internal reference gene). Cutoff
points were calculated according to median value for the mRNA
expression of each gene. Samples with mRNA expression above or
equal to the median were considered as samples with high
expression, whereas those with value below the median as samples
with low expression. In addition, the gene mRNA expression levels
were divided in quartiles (Q1 (lowest levels)–Q4 (highest levels)).
Patients in the middle quartiles were considered as one group
(Q2þQ3), and comparisons were performed among all three
groups (Q1, Q2þ3, Q4).
Statistical analyses
The Mann–Whitney t-test was used to test a significant association
between the continuous variable of gene expression and the
dichotomous variables. Pearson’s exact test was used to evaluate
the correlation between RRM1 and RRM2 mRNA expression. The
w
2 test was used for the association between gene expression and
response. Binary logistic regression was carried out to evaluate
which of the significant factors in the w
2 analysis had a significant
influence on response. Cox’s proportional hazards multivariate
analysis was used to evaluate which of the significant factors at the
univariate analysis had a significant influence on time to
progression and overall survival. Logistic regression analysis was
used to evaluate which of the significant factors at the univariate
analysis had a significant influence on response. Statistical
significance was set at P¼0.05.
RESULTS
Patient characteristics
A total of 53 patients were enrolled. Patient characteristics are
shown in Table 1. Forty-two (79%) samples were successfully
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samplified; the remaining 11 samples were not quantifiable because
of insufficient tumour tissue or large amounts of necrosis in the
tumour sample (Figure 1).
Clinical outcome
In an intent-to-treat analysis, complete response was observed
in four (7.5%) and partial response in 15 (28.3%) patients
(overall response rate 35.8; 95% confidence interval: 19.6–
46.9%). Fifteen (28.3%) patients had stable disease and
20 (37.7%) had progressive disease. There was no correlation
between response and known clinical parameters (age, PS, disease
stage or the number of involved sites). After a median follow-up
period of 7.5 months (range, 0.5–46.2), the median time to
progression was 4.3 months (range, 0.2–34.9), and the median
overall survival was 10.1 months (range, 0.5–46.2); the 1-year
survival rate was 40.2%. For the 42 patients evaluable for RRM1
and RRM2 mRNA expression, overall response rate was 30%,
time to progression was 3.9 months and median overall survival
was 9.8 months.
RRM1 and RRM2 mRNA expression and clinical outcome
Tumour RRM1 and RRM2 mRNA expression levels ranged
from 0.1 to 8.9 (median 1.04; mean 1.8±s.d. 1.15) and from
0.97 to 114.3 (median 8.83; mean 17.69±s.d. 20.56), respectively.
There was no correlation between age, gender, PS or disease
stage and RRM1 or RRM2 mRNA levels. Using the median
expression levels as cutoff values, high (above or equal to the
median) RRM1 mRNA expression was observed in 25 (59.5%)
and low (below the median) in 17 (40.5%) patients, and high
RRM2 mRNA expression in 22 (52.4%) and low in 20 (47.6%)
patients. When patients were divided into quartiles according
to their expression levels of RRM1, 11 patients were in the
lowest quartile (0.1–0.36), 20 patients were in the intermediate
quartiles (0.36–2.11) and 11 patients were in the highest quartile
(2.11–8.9). When patients were divided into quartiles according
to their expression levels of RRM2, 11 patients were in the
lowest quartile (0.97–4.03), 20 patients in the intermediate
quartiles (4.03–21.75) and 11 in the highest quartile (21.75–
114.3) (Table 2).
When patients were divided into those with low vs those
with high RRM1 and RRM2 expression, no correlation was
found between RRM1 expression and clinical outcome. However,
the 20 patients with low RRM2 expression attained a significantly
higher response rate than the 22 patients with high RRM2
expression (54.5 vs 9%; P¼0.002); there was no significant
correlation between RRM2 expression and time to progression
or survival (Table 2). When patients were divided by quartiles of
RRM1 and RRM2 expression, the 11 patients in the lowest quartile
of RRM1 expression had a longer time to progression (7.1 vs 1.7
months; P¼0.04) and overall survival (10.6 vs 1.6 months;
P¼0.02) than the 11 patients in the highest quartile; in addition,
there was a nonsignificant trend towards a higher response rate for
patients in the lowest quartile, compared to those in the highest
quartile (45.5 vs 20%; P¼0.062) (Table 2). The 11 patients in the
lowest quartile of RMM2 expression attained a significantly higher
response rate than the 11 patients in the highest quartile (45.5 vs
0%; P¼0.016), but there was no significant difference in time to
progression or overall survival according to RRM2 expression
quartiles (Table 2).
When patients were classified according to their expression
levels of both RRM1 and RRM2, the 10 patients with low levels of
both RRM1 and RRM2 attained a higher response rate, time to
progression and overall survival than the seven patients with high
levels of both genes (response rate: 60 vs 14.2%, P¼0.049; time to
progression: 9.9 vs 2.3 months, P¼0.003 (Figure 2); overall
survival: 15.4 vs 3.6 months, P¼0.031 (Figure 3)) (Table 2). No
other significant correlation was observed between clinical out-
come and the combined expression levels of RRM1 and RRM2
mRNA (Table 2).
Table 1 Patient characteristics
Patients
Number %
Gender
Male 45 85
Female 8 15
Age (years)
Median 60
Range 39–75
Performance status (ECOG)
03 5 6 6
11 6 3 0
22 4
Stage
IIIB 12 23
IV 41 77
Number of organs involved
11 6 3 0
22 0 3 8
X31 7 3 2
RRM1 mRNA expression
Samples analysed 53 100
Samples successfully amplified 42 79
Missing values 11 21
RRM2 mRNA expression
Samples analysed 53 100
Samples successfully amplified 42 79
Missing values 11 21
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; RRM1¼ribonucleo-
tide reductase subunit M1; RRM2¼ribonucleotide reductase subunit M2.
55 patients eligible for the study
55 patients enroled
Successful amplification of RRM1 and RRM2
genes in 42 patients' primary tumour samples
42 patients analysed for RRM1 and RRM2
Two patients found ineligible
(cytologically confirmed lung
adenocarcinomas, no biopsy)
Seven samples (bronchial biopsies) with very 
few tumour cells; four samples with no tumour 
cells (necrosis and lymphocyte infiltration)
Figure 1 Flow chart showing patient progress through the study.
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The univariate analysis (Table 3) showed that RRM2 mRNA
expression was significantly associated with response rate
(Po0.001). The multivariate analysis showed that high expression
of RRM2 – but not of RRM1 – was significantly associated with
poor response (odds ratio: 31.5; P¼0.002) (Table 3). In the
univariate and multivariate analyses of survival, only PS emerged
as a significant prognostic factor for survival (hazard ratio: 2.26;
P¼0.024) (Table 4).
DISCUSSION
The present study has demonstrated for the first time a positive
correlation between tumour mRNA expression of RRM2 and
response to a gemcitabine-based combination in patients with lung
adenocarcinomas. Low RRM2 mRNA expression was associated
Table 2 Tumour RRM1 and RRM2 mRNA expression and clinical outcome
Time to progression (months) Overall survival (months) Response N (%)
N (%) Median (95% CI) P Median (95% CI) P CR+PR SD+PD P
High vs low Low RRM1 17 (40.5) 4.0 (3.1–5.8) 0.43 9.8 (4.2–15.4) 0.31 7 (41) 10 (59) 0.23
High RRM1 25 (59.5) 3.7 (1.9–5.4) 5.5 (0.7–10.3) 6 (24) 19 (76)
Low RRM2 20 (47.6) 3.6 6.5 11 (54.5) 9 (64.5) 0.002
High RRM2 22 (52.4) 4.9 0.38 6.8 0.9 2 (9) 19 (91)
Quartiles RRM1 by quartiles
Q1 (low) 11 7.1(1.8–12.4) 0.04
a 10.6 (5.6–15.5) 0.02
a 5 (45.5) 6 (54.5) 0.06
a
Q2+Q3 20 4.0 (0.8–7.2) NS
b 5.5 (3.8–12.6) NS
b 6 (30) 70 NS
b
Q4 (high) 11 1.73 (0.6–2.0) 1.6 (1.4–1.8) 2 (20) 80
RRM2 by quartiles
Q1 (low) 11 5 (1.6–9.8) 0.18
a 10.6 (4.3–19.7) 0.14
a 5 (45.5) 6 (54.5) 0.016
a
Q2+Q3 20 3.6 (1.1–6.1) NS
b 9.5 (1.4–16.1) NS
b 8 (40) 12 (60) 0.035
c
Q4 (high) 11 3.6 (0.1–5.6) 5.5 (0.5–10.5) 0 (0) 11 (100)
RRM1 and RRM2 Low RRM1 and low RRM2 10 9.9 (1.9–17.8) 0.003
d 15.4 (7.0–30.1) 0.03
d 6 (60) 4 (40) 0.049
d
High RRM1 and high RRM2 7 2.3 (0–5.3) 3.6 (0–8.2) 1 (14.2) 6 (85.8)
Low RRM1 and high RRM2 15 3.6 (0.32–6.8) 0.1
e 6.4 (4.4–8.3) 0.17
e 3 (20) 12 (80) 0.05
e
High RRM1 and low RRM2 10 3.8 (0–7.2) 0.4
e 6.9 (0.1–9.3) 0.15
e 3 (30) 7 (70) 0.06
e
Abbreviations: CI¼confidence interval; CR¼complete response; PD¼progressive disease; PR¼partial response; SD¼stable disease; RRM1¼ribonucleotide reductase
subunit M1; RRM2¼ribonucleotide reductase subunit M2.
aP-value: Q1 vs Q4.
bP-value: Q1 vs Q2+3 and Q2+3 vs Q4.
cP-value: Q2+3 vs Q4.
dP-value: both low vs both high.
eBoth low vs RRM1 low/RRM2 high or RRM1 high/RRM2 low.
1.0
P=0.003
0.8
0.6
0.4
0.2
Low RRM1 and low RRM2 (n=10): 
TTP 7.1 m (95% CI:1.9–17.8)
High RRM1 and high RRM2 
(n=7): 
TTP 1.73 m (95% CI:0–5.27)
0.0
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Figure 2 Time to progression according to low vs high levels of both
RRM1 and RRM2.
Table 3 Univariate and multivariate analyses for response
Odds ratio 95% CI P-value
Univariate analysis
Age (p65 vs 465 years) 1.01 0.69–1.34 0.97
Gender (male vs female) 1.23 0.7–1.83 0.64
Performance status (0 vs 1–2) 1.54 0.87–2.04 0.15
Stage (III vs IV) 1.12 0.67–1.41 0.42
RRM1 mRNA (low vs high) 1.38 0.67–2.91 0.31
RRM2 mRNA (high vs low) 37.5 3.8–369.8 o0.001
Multivariate analysis
RRM2 mRNA (high vs low) 31.5 3.5–283.3 0.002
Abbreviations: CI¼confidence interval; RRM1¼ribonucleotide reductase subunit
M1; RRM2¼ribonucleotide reductase subunit M2.
1.0
0.8
0.6
%
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0.4
0.2
0.0
01 02 0
Low RRM1 and RRM2 (n=10): 
Mos: 15.4 m (95% CI: 7.03–30.01)
High RRM1 and RRM2 (n=7): 
Mos: 3.6 m (95% CI: 0–8.2)
Months
P=0.031
30 40
Figure 3 Overall survival according to low vs high levels of both RRM1
and RRM2.
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swith a significantly higher response rate compared to that of
patients with high RRM2 mRNA expression. In fact, only two (9%)
of 22 patients with high RRM2 expression responded to docetaxel/
gemcitabine. Furthermore, the multivariate analysis revealed that
RRM2 expression was an independent marker for response
(P¼0.002). The probability of response in patients with low
RRM2 expression was 31.5 times higher than that of patients with
high RRM2 expression. In addition, patients with RRM1 mRNA
expression in the lowest quartile attained a significantly higher
time to progression (P¼0.044) and overall survival (P¼0.02) and
showed a trend towards a higher response rate (P¼0.06),
compared to patients in the highest quartile of RRM1 expression.
Furthermore, patients with low expression of both RRM1 and
RRM2 derived the maximum benefit from docetaxel/gemcitabine,
with a significantly higher response rate (P¼0.049), time to
progression (P¼0.003) and overall survival (P¼0.031). Despite
the fact that caution is needed when interpreting these results, due
to the small number of patients evaluated, our data suggest that the
molecular profile of the primary tumour could be used as a marker
for response and clinical outcome of patients with lung
adenocarcinomas treated with docetaxel/gemcitabine.
The results of the present study are along the lines of several
other reports demonstrating that tumour mRNA expression of
RRM1 was correlated with clinical response to gemcitabine/
cisplatin in stage IV NSCLC (Rosell et al, 2003, 2004; Ceppi et al,
2006). In addition, inhibition of RRM2 mRNA expression in vitro
with the use of interference RNA enhanced chemosensitivity of
pancreatic adenocarcinomas to gemcitabine (Duxbury et al, 2003,
2004). Apart from the well-known role of RRM2 in maintaining
DNA integrity, several studies have reported that RRM2 has
additional functions that influence the invasive phenotype.
Increased RRM1 and RRM2 activity was identified in highly
metastatic tumour cells (Schallreuter et al, 1992), whereas over-
expression of RRM2 in human oral carcinoma cells was shown to
be associated with increased invasive potential (Zhou et al, 1998),
probably through NF-kB and MMP-9 (Duxbury and Whang, 2007).
In conclusion, the results of the present study revealed that the
efficacy of docetaxel/gemcitabine in lung adenocarcinoma patients
is associated with RRM1 and RRM2 mRNA expression, thus
indicating the importance of tailoring treatment. As this study was
conducted in patients with lung adenocarcinomas, it is unclear
whether these observations are also valid in patients with
squamous cell carcinomas, and the sample size in the present
study requires the results to be interpreted with caution. The role
of RRM1 and RRM2 should be further investigated in an
adequately statistically powered, independent set of samples. In
addition, prospective studies using gemcitabine, either as a single
agent or in combination with other drugs, are warranted to further
clarify the relation between RRM1 and RRM2 coexpression and
tumour chemosensitivity. The potential predictive role of RRM1
and RRM2 mRNA expression warrants examination in malig-
nancies where gemcitabine-based therapy is standard, such as
pancreatic cancer. Finally, prospective studies are warranted to
clarify the importance of RRM1 and RRM2 expression for tailoring
treatment of patients with NSCLC.
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